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acids is superior to aspirin alone to prevent
or ameliorate sepsis or ARDS
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Abstract
It has been suggested that aspirin may be of benefit in treating sepsis and ARDS in view of its ability to block
cyclo-oxygenase-1 (COX-1) and COX-2 activities; inhibit nuclear factor kappa B (NF-κB); enhance the production
of endothelial nitric oxide (eNO) and lipoxin A4 (LXA4). Our previous studies revealed that plasma phospholipid
content of arachidonic acid (AA) and eicosapentaenoic acid (EPA) is low in patients with sepsis. This implies that
beneficial actions of aspirin in sepsis and ARDS is unlikely to be obtained in view of deficiency of AA and EPA, the
precursors of LXA4 and resolvins respectively that are potent anti-inflammatory compounds and enhancers of eNO
generation. In view of this, I propose that a combination of aspirin and AA and EPA (and possibly, docosahexaenoic
acid, DHA) is likely to be superior in the management of sepsis and ARDS compared to aspirin alone. This
suggestion is supported by the recent observation that trauma patients with uncomplicated recoveries had higher
resolvin pathway gene expression and lower gene expression ratios of leukotriene: resolvin pathways.
Keywords: Aspirin, Essential fatty acids, Acute respiratory distress syndrome, Sepsis, Lipoxin A4, Resolvin, Protectins,
Arachidonic acid, Eicosapentaenoic acid, Docosahexaenoic acid, Nitric oxide, Cyclo-oxygenase, Lipoxygenase
Introduction
ARDS (acute respiratory distress syndrome), sepsis and
septic shock can lead to multiorgan dysfunction syn-
drome (MODS) that cause death among patients in
non-coronary critical care units. Several mechanisms
contribute to the pathogenesis of MODS. Some of these
include: bacterial toxins, inflammatory mediators secreted
by neutrophils, macrophages, and T cells; endothelial in-
jury, disturbed homeostasis, and microcirculatory failure.
Though the exact pathobiology of ARDS, sepsis and septic
shock is not clear, there is significant evidence to suggest
that inflammation and disruption of the hemostatic sys-
tem as a result of platelet-leucocyte interaction and conse-
quent enhanced production of inflammatory cytokines
such as interleukin (IL)-1β, IL-8, monocyte chemotactic
protein 1 and tumour necrosis factor-alpha (TNF-α) play
a major role [1–5]. The septic response is a complex chain
of events involving inflammatory and antiinflammatory
processes, humoral and cellular reactions and circulatory
abnormalities [6–8]. Sepsis and evaluation of its severity is
complicated by the highly variable and non-specific nature
of the signs and symptoms of sepsis [9].
Sepsis is now defined as evidence of infection plus
life-threatening organ dysfunction, clinically character-
ized by an acute change of 2 points or greater in the
SOFA (Sequential [Sepsis-related] Organ Failure Assess-
ment) score. The criteria for septic shock include sepsis
with fluid-unresponsive hypotension, serum lactate level
greater than 2 mmol/L, and the need for vasopressors to
maintain mean arterial pressure of 65 mmHg or greater.
The new definitions [10–13] eliminated mention of SIRS
(systemic inflammatory response syndrome). Components
of SIRS include tachycardia, tachypnea, hyperthermia or
hypothermia, and abnormalities in peripheral white blood
cell count that are nearly ubiquitous in hospitalized pa-
tients and occur in many benign conditions, both related
and not related to infection, and thus are not adequately
specific for the diagnosis of sepsis. But, it needs to be
noted that patients with infections and organ dysfunction
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are exceptionally heterogeneous in terms of demographic
characteristics, underlying conditions, microbiology, and
other clinically relevant factors.
The close link among inflammation, disruption of the
hemostatic system as a result of platelet-leucocyte inter-
action and altered production of inflammatory cytokines
seen in sepsis led to the suggestion that thrombosis, in-
flammation and platelets play a significant role in sepsis
and hence, anti-platelet medications such as aspirin could
be of benefit in sepsis and ARDS [5, 6]. The potential
beneficial action of aspirin in ARDS and sepsis has been
attributed to its ability to (i) inhibition of COX; (ii)
inhibition of nuclear factor kappa B (NFκB); (iii) increase
in the production of endothelial nitric oxide (eNO) and
inhibition of inducible NO generation; (iv) enhanced pro-
duction of lipoxin A4 (LXA4) and (v) decrease in the
generation of platelet aggregator thromboxane A2 (TXA2)
and enhance prostacyclin (PGI2) production [5, 14–20].
The putative beneficial role of aspirin in ARDS and sep-
sis is supported by the observation that aspirin treatment
is effective in murine models of these diseases [5, 21–24].
These results are supported from human observational
studies wherein it was noted that aspirin treatment could
have decreased risk of developing sepsis and ARDS; re-
duced severity when they do develop sepsis or ARDS and
decreased mortality [5, 24–37]. But these results are not
without controversy [28]. These studies are interesting
and open a new avenue of managing sepsis and ARDS.
But, I suggest that use of aspirin alone may not be ad-
equate in sepsis and ARDS. I propose that a combination
of aspirin and unsaturated fatty acids: arachidonic acid
(AA, 20:4 n-6), eicosapentaenoic acid (EPA, 20:5 n-3) and
docosahexaenoic acid (DHA, 22:6 n-3), the precursors of
anti-inflammatory bioactive lipids lipoxin A4 (from AA);
resolvins (from EPA and DHA); and protectins and mare-
sins (from DHA) [38–40] is likely to be more suited and
beneficial in managing sepsis and ARDS.
Essential fatty acid (EFA) metabolism is altered in
sepsis and ARDS
Previously it was shown that AA metabolism is mark-
edly affected in patients with sepsis [41]. It was reported
that AA, AA analogues, and the cyclooxygenase-
associated metabolites: prostaglandin E2 (PGE2), 11-
hydroxyeicosatetraenoic acid, and thromboxane B2
(TXB2) were identified as differentiating metabolites
between septic patients and healthy subjects. AA, its
analogues, and PGE2 and TXB2 differed at baseline. It
is interesting that the inducibility of AA and the cyclo-
oxygenase metabolites 11-hydroxyeicosatetraenoic and
PGE2 were reduced by 80% to 90% in sepsis. Further-
more, the degree of the inducibility was associated with
severity of sepsis and clinical outcome. A reduced induc-
ibility of COX-2 but preserved inducibility of mPGES-1
on gene expression level was confirmed in an inde-
pendent cohort of septic patients compared to healthy
controls [41].
Previously, we reported that patients with sepsis showed
increased production of superoxide anion and hydrogen
peroxide (H2O2) by their peripheral leukocytes; and
enhanced levels of circulating lipid peroxides with a
concomitant decrease in plasma phospholipid content
of GLA, DGLA, AA of n-6 series and ALA, EPA and
DHA of n-3 series (see Table 1) [42]. These findings
imply that decreased production of lipoxin A4 (LXA4),
resolvins, protectins and maresins may occur due to a
deficiency of their precursors (AA, EPA and DHA),
which are potent anti-inflammatory bioactive lipids that
may lead to perpetuation of the inflammatory process
seen in sepsis and ARDS. Though the exact cause for
this deficiency of GLA, DGLA, AA, ALA, EPA and
DHA is not clear, this may, in part be due to their per-
oxidation as a result of enhanced generation of free
radicals and the ability of TNF-α to suppress the forma-
tion of DGLA, AA, EPA and DHA. In an in vitro study,
it was noted that TNF-α incubation of HUVEC (human
umbilical vascular endothelial cells) caused an EFA de-
ficiency state reminiscent of long-term malnutrition
[43]. This interaction between TNF-α and possibly,
other pro-inflammatory cytokines and EFA metabolism
is significant since several PUFAs (polyunsaturated fatty
acids) inhibit TNF-α and IL-6 production and excess
free radical generation [38]. Thus, induction of EFA defi-
ciency state by TNF-α in sepsis (and possibly, other condi-
tions in which there is enhanced production of TNF-α
occurs) may exacerbate the inflammatory process due to
the absence of negative feedback control exerted by
PUFAs and their anti-inflammatory metabolites: LXA4,
Table 1 Leukocyte free radical generation, plasma lipid peroxides
and phospholipid content of unsaturated fatty acids in patients
with sepsis
Measurement Control (n = 10) Sepsis (n =14)
μM of formazan (O2−1) without PMA 4.5 ± 1.0 6.48 ± 3.0*
with PMA 40.3 ± 9.7 62.2 ± 18*
μM of H2O2 without PMA 4.76 ± 0.56 9.0 ± 4.3*
With PMA 44.2 ± 6.16 70.3 ± 50
nmoles of MDA-eq 1.56 ± 0.36 2.37 ± 0.6*
18:3 n-6 (GLA) 0.13 ± 0.09 0.04 ± 0.05*
20:3 n-6 (DGLA) 3.2 ± 0.79 0.46 ± 0.54*
20:4 n-6 (AA) 8.8 ± 2.0 5.8 ± 1.6*
18:3 n-3 (ALA) 0.27 ± 0.12 0.16 ± 0.11*
20:5 n-3 (EPA) 0.25 ± 0.26 0.01 ± 0.01*
22:6 n-3 (DHA) 1.43 ± 0.43 1.2 ± 1.14
All values are expressed as mean ± SE. *P < 0.05 compared to control. All fatty
acids are expressed as % of PL (phospholipid)
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resolvins, protectins and maresins. In such an instance of
EFA deficiency states, administration of aspirin may not
be able to enhance the formation of LXA4 and aspirin-
triggered 15-epi-lipoxin A4 (ATL) (from AA), resolvins
(from EPA and DHA), protectins and maresins (from
DHA) due to decreased levels of their precursors AA,
EPA and DHA. In view of this, it is unlikely that aspirin
alone will be of significant benefit in ARDS and sepsis
wherein AA, EPA and DHA deficiency is present. This ar-
gument is supported by the observation that administra-
tion of aspirin produced controversial results in sepsis and
ARDS [28]. I propose that co-administration of PUFAs
(especially AA, EPA and DHA) along with aspirin is likely
to be of more beneficial and rational than administration
of aspirin alone. Such a combined provision of PUFAs
(especially AA, EPA and DHA) and aspirin is expected to
lead to enhanced formation of LXA4, resolvins, protectins,
maresins and 15-epi LXA4 (ATL) due to the availability of
precursors of these anti-inflammatory bioactive lipids
(see Fig. 1).
Lipoxins, resolvins and protectins in sepsis and
ARDS
The role of PUFAs and their anti-inflammatory bioactive
lipids in sepsis is supported by the observation that in the
cecal ligation and puncture model of sepsis in rats admin-
istration of LXA4 (40 μg/kg intraperitoneally) 5 h after
surgery increased survival compared to control [44]. In
this study, it was noted that plasma IL-6, monocyte
chemotactic protein 1 and IL-10 levels were reduced in
addition to reduced phosphorylation of the p65 subunit of
NF-κB in LXA4 treated rats suggesting that LXA4 re-
duced systemic inflammatory events. In addition, LXA4
reduced bacterial load and increased peritoneal macro-
phage number that accounted for increased bacterial
clearance. These results suggested that LXA4 increased
Fig. 1 Scheme showing metabolism of EFAs, formation of their metabolites PGs, LTs, TXs, LXA4, resolvins, protectins and maresins and their
actions on cytokines, ROS (reactive oxygen species), NO (nitric oxide), carbon monoxide (a product of hemeoxygenase −1) and relevance of
aspirin in this chain of events and their role in sepsis and ARDS. Ach = Acetylcholine
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survival in sepsis by reducing systemic inflammation [44].
In this context, it is noteworthy that LXA4 but not its
stable analog 15-epi-16-(para-fluorophenoxy)-lipoxin A4
methyl ester (when both were given at a dose of 7 μg/kg,
i.v.) in the cecal ligation and puncture (CLP) model of
sepsis increased 8 day survival despite the fact that both
compounds reduced plasma TNF-α and IL-6 concentra-
tions. It was observed that LXA4 analog increased plasma
IL-10 concentrations compared to rats given LXA4, while
LXA4 reduced blood bacterial load but LXA4 analog did
not [45]. These results suggest that endogenous LXA4 is
superior in the management of sepsis compared to its
more stable and structural analogs that one need to note
while developing therapies based on LXA4.
These results are further supported by the observa-
tion that resolvin D2, identified in resolving exudates,
decreased leukocyte–endothelial interactions in vivo by
endothelial-dependent nitric oxide production, and by
direct modulation of leukocyte adhesion receptor ex-
pression, decreased both local and systemic bacterial
burden, excessive cytokine production and neutrophil
recruitment, while increasing peritoneal mononuclear
cells and macrophage phagocytosis and thus, increased
survival from sepsis induced by caecal ligation and
puncture and surgery [46]. These beneficial actions of
resolvin D2 seem to be mediated by its receptor GPR-
18 (G-protein coupled receptor-18) that is expressed on
human leukocytes, monocytes and macrophages. The
ability of resolvin D2 to limit PMN infiltration, enhance
phagocyte clearance of bacteria and accelerate reso-
lution of inflammation was lost in GPR-18-deficient
mice emphasizing the role of resolvin D2-GPR-18 reso-
lution axis to control bacterial infections and prevent
sepsis and promote organ protection [47]. Thus, LXA4
and resolvin D2 and, possibly, other resolvins, protec-
tins and maresins are of significant benefit in sepsis and
ARDS.
In this context, it is noteworthy that the anti-
inflammatory and inflammation resolution promotor
actions of LXA4, resolvins, protectins and maresins is
balanced and antagonized by pro-inflammatory bio-
active lipid leukotriene B4 (LTB4). Mice with type 1
diabetes that are susceptible to chronic systemic in-
flammation and enhanced susceptibility to sepsis
showed increased expression of Alox5, which encodes
5-lipoxygenase (5-LOX), and enhanced concentrations
of IL-1β in peritoneal macrophages and serum, while
treatment with insulin reduced LTB4 concentrations.
On the other hand, type 1 diabetic mice lacking 5-LOX
or the receptor for LTB4 produced less IL-1β, survived
polymicrobial sepsis, and had decreased bacterial
counts [48]. These results [44–48] imply that under
normal physiological condition there is a balance main-
tained between pro- and anti-inflammatory bioactive
lipids (LTB4 vs LXA4/resolvins/protectins/maresins) to
limit inflammation, regulate production of various cyto-
kines, control bacterial proliferation and their ability to
produce inflammation and ultimately control, prevent
and help in the recovery from sepsis and ARDS as pro-
posed previously [49, 50].
Pneumosepsis induced in mice by Klebsiella pneumo-
niae produced an early increase in LXA4 and its recep-
tor FPR2/ALX lung expression, local and systemic
infection and inflammation, and mortality, suggesting
that excess production of LXA4 may also be harmful.
On the other hand, treatment with LXA4 antagonist in
early sepsis increased leukocyte migration to the focus,
and reduced bacterial load and dissemination and im-
proved survival. In contrast, it was also noted that treat-
ment with LXA4 in early sepsis decreased cell migration
and worsened the infection. On the other hand, in late
sepsis, LXA4 improved the survival rate by reducing the
excessive inflammatory response. Thus, LXA4 and its re-
ceptor FPR2/ALX seem to have a dual role in sepsis and
its beneficial or harmful effects are critically dependent
on the time [51]. It is likely that resolvins, protectins and
maresins also may have actions similar to LXA4 in sep-
sis. These results emphasize the importance of timing in
the use of proresolving anti-inflammatory bioactive
lipids in the management of sepsis and ARDS.
The ability of insulin to suppress LTB4 and IL-1β
production is in tune with the previous suggestion that
insulin has anti-inflammatory actions and its infusion
may be of benefit in sepsis and ARDS [52–55]. Further-
more, insulin is known to activate Δ6 and Δ5 desaturases
that are needed for the conversion of EFAs: linoleic acid
(LA, 18:2 n-6) and α-linolenic acid (ALA, 18:3 n-3) to
their long-chain metabolites GLA, DGLA, AA, and EPA
and DHA respectively [20]. Thus, a co-ordinated and
negative and positive feedback regulatory action among
insulin, Δ6 and Δ5 desaturases, various PUFAs and their
pro- and anti-inflammatory bioactive lipids and cytokines
is needed to control infection and recover from sepsis and
ARDS.
PUFAs, LXA4, resolvins, protectins and maresins
have antibiotic-like actions and modulate
phagocytosis
It is interesting to note that PUFAs: LA, ALA, GLA, AA,
EPA and DHA have anti-bacterial actions [56, 57]. Recent
studies showed that GLA and AA enhance the activities of
ceftazidime and amikacin on multidrug-resistant Pseudo-
monas aeruginosa and Escherichia coli both in vitro and
in vivo. PUFAs are present in all cell membranes and re-
leased in response to many stimuli especially on exposure
to endotoxin (lipopolysaccharide: LPS) of bacteria due to
activation of phospholipase A2 (PLA2). These results sug-
gest that endogenous unsaturated fatty acids may function
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as natural antibiotics. This raises the intriguing possibility
that a deficiency of these endogenous unsaturated fatty
acids (especially of GLA and AA and EPA) may predis-
pose an individual to various infections. When the suscep-
tibility of 242 strains of Staphylococcus aureus and 117
strains of streptococci of groups A, B, C, and G to various
fatty acids were studied, it was found that GLA, AA, EPA
and DHA are effective against them [58–64]. Similar, if
not identical, anti-bacterial activity was shown to be pos-
sessed by resolvins and protectins which enhanced anti-
biotic ciprofloxacin therapeutic actions and enhanced
vancomycin clearance of Staphylococcus aureus [65]. But,
it is not yet clear whether resolvins, protectins, maresins
and LXA4 can directly inhibit bacterial growth similar to
PUFAs.
It is well known that hyperactivation of neutrophils that
is seen in early phase of sepsis leads to tissue injury. In
contrast, neutrophil dysregulation in the form of reduced
levels of migration, decreased apoptosis and inadequate
phagocytosis that occurs in the later part of sepsis impairs
host’s ability to clear infection. A recent study [66] showed
that in the cecal ligation and puncture rat model of sepsis,
LXA4 given after 1 h reduced blood bacterial load at 24 h,
decreased neutrophil migration to the peritoneum but
augmented blood neutrophil phagocytic ability and pro-
moted apoptosis without affecting free radical production.
In addition, LXA4 increased peritoneal neutrophil
phagocytic ability without affecting apoptosis or free
radical production suggesting that effects of LXA4 were
compartment specific. Incubation ex vivo LXA4 (1 nM)
increased phagocytosis in blood neutrophils without
affecting apoptosis or free radical production. These re-
sults suggest that LXA4 increased neutrophil bacteria
clearing function without excessive free radical produc-
tion, a beneficial action needed in sepsis. Similar results
were also obtained in acute lung injury (ALI).
ALI is a severe illness with excess mortality and no
specific therapy and is often seen in sepsis that leads to
ARDS. In its early exudative phase, neutrophil activation
and accumulation in the lung lead to hypoxemia, wide-
spread tissue damage, and respiratory failure (ARDS). In
a spontaneously resolving experimental murine model of
ALI, inhibition of COX-2 blocked resolution of ALI.
Both LXA4 and 15-epi-LXA4 produced dramatic protec-
tion from ALI, indicating that LXA4 has a protective
role in ALI and ARDS and COX-2 expression is needed
for this purpose [67]. These results are supported by the
observation that inhalation of LPS (lipopolysaccharide)-
induced increased inflammatory cell counts, TNF-α and
protein concentration in bronchoalveolar lavage fluid
and lung injury and edema can be prevented by aspirin
triggered lipoxin A4 (ATL, 15-epi-16-parafluorophenoxy
lipoxin A4), a stable analogue of LXA4 [68]. In addition,
ATL promoted the formation of heme oxygenase-1 in
the lung tissues. Heme oxygenase-1 activity, which of-
fers protection against prooxidant insults [69], was also
increased in the lung tissues after ATL treatment, dem-
onstrating that ATL significantly reduces LPS-induced
acute lung injury (and ARDS) in mice. In this context,
it is interesting to note that activation of the efferent
vagus nerve inhibits the release of TNF-α and attenu-
ates the development of endotoxin-induced shock in
rodents [70]. Stimulation of the efferent vagus nerve acti-
vates the release of acetylcholine. There is indirect evi-
dence to suggest that acetylcholine, an anti-inflammatory
molecule, augments LXA4 production [71]. Thus, there
appears to be a link between neurohumoral pathway and
anti-inflammatory lipid mediators such as LXA4, resolvins
and protectins.
Clinical studies
Despite many in vitro and animal studies, there is scarcity
of information on the role of LXA4, resolvins, protectins
and maresins in patients with sepsis and ARDS. In a re-
cent study, it was noted that the ratio of expression
between endogenous proinflammatory (leukotrienes) and
proresolving (resolvins) lipid mediator pathway genes was
significantly higher in patients with prolonged, compli-
cated recovery after blunt trauma, suggesting that patients
with complicated recoveries have dysregulated lipid medi-
ator signaling [72]. It is likely that resolvins, protectins
and maresins also may have actions similar to LXA4 in
sepsis. These results emphasize the importance of timing
in the use of proresolving anti-inflammatory bioactive
lipids in the management of sepsis and ARDS.
Examination of 7,945 intensive care unit admissions
showed a strong association between acetyl salicylic acid
and survival in intensive care unit SIRS and sepsis pa-
tients. These results led to the suggestion that low doses
of acetyl salicylic acid, acting through 15-epi-lipoxin A4,
are responsible for its beneficial action in reducing the
severity of SIRS and reduced mortality [30].
Despite many studies in experimental animals showing
beneficial action of PUFAs especially of EPA and DHA
(given in the form of fish oil in majority of the studies)
[73–75] in sepsis, these beneficial actions were not uni-
formly seen in patients [76, 77]. But some clinical stud-
ies did show that PUFAs may be beneficial in patients
with sepsis [78–84]. These contradictory results [73–84]
led ‘Surviving Sepsis Campaign: International Guidelines
for Management of Severe Sepsis and Septic Shock’ to
recommend that there is no sufficient evidence for the
use of immunomodulating nutritional supplements such
as PUFAs in sepsis [85], though larger trials are ongoing.
Based on these evidences, it is suggested that better de-
fined clinical studies with different combinations of
PUFAs (example: EPA ±DHA ±GLA ±AA ±DPA) using
different doses of fatty acids for various periods of time
Das Lipids in Health and Disease  (2016) 15:206 Page 5 of 8
(example: few hours to days to weeks) are needed to de-
termine the efficacy of PUFAs in sepsis and ARDS.
Conclusions
Obviously sepsis and ARDS are as a result of multiple
causes with multiple mediators involved in their patho-
genesis. Though the concept of use of aspirin in sepsis
and ARDS appears interesting and novel, the presence
of EFA deficiency and an imbalance between pro and
anti-inflammatory molecules suggests that perhaps, use
of GLA, AA, EPA and DHA along with aspirin to en-
hance the production of anti-inflammatory LXA4,
resolvins, protectins and maresins is more prudent. A
recent multicentre study in patients undergoing mech-
anical ventilation with severe sepsis and septic shock
reported a 19.4% reduction in the absolute risk of mor-
tality, improved oxygenation, more days free from
mechanical ventilation, decreased stay at the ICU and
less development of new organic dysfunctions in the
group that received EPA, LA and anti-oxidants [86]. A
more recent multicenter study showed a significant de-
crease in the mean length of stay in the ICU without af-
fecting mortality or infectious complications in the
intention to treat analysis in those who received EPA
and GLA infusions [76]. It was reported that inclusion
of fish oil in parenteral nutrition provided to septic ICU
patients increased plasma EPA, suppressed inflammatory
cytokine concentrations and improves gas exchange [87].
These changes are associated with a tendency towards
shorter length of hospital stay. It is possible that had the
investigators included aspirin and DHA and AA in these
in the infusions, perhaps the results would have been
more encouraging.
In this context, it is worthwhile to measure plasma
levels of lipid peroxides, various cytokines, PUFAs, LXA4,
resolvins, protectins, maresins, LTB4 and correlate their
concentrations to the severity and prognosis of sepsis and
ARDS especially prior to embarking on the trial of aspirin
with various PUFAs in order to know the dynamics of
their changes in these patients as suggested previously
[50]. Such a knowledge will gives us a better handle as to
how much and when to administer aspirin, various PUFAs
and possibly, LXA4, resolvins, protectins and maresins to
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